-
Potential CF Therapy MRT5005 Moving Forward Through Phase 1/2 Trial
An ongoing Phase 1/2 clinical trial exploring Translate Bio’s investigational therapy MRT5005 will start testing multiple ascending doses (MAD) in patients with cystic fibrosis (CF). Click here to learn more about this trial.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.